Clinical Trial Update: A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males [Phase 3]

View source ↗

Summary

Phase III trial evaluating the efficacy, immunogenicity, and safety of a recombinant HPV9-valent vaccine in Chinese males for prevention of penile and anal intr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anal Cancer
• Anal Intraepithelial Neoplasia
• Genital Warts
• Penile Cancer
• Penile Intraepithelial Neoplasia

Drugs mentioned

• HPV9-valent recombinant vaccine (types 6,11,16,18,31,33,45,52,58) (Human papillomavirus vaccine, 9-valent)

Snippet

Sponsor: Xiamen University | Conditions: Penile/Perineal /Perianal Intraepithelial Neoplasia, Anal Intraepithelial Neoplasia | Phase 3 | Status: ACTIVE_NOT_RECRUITING